M. S. Raab, K. Podar, I. Breitkreutz, P. G. Richardson, and K. C. Anderson, Multiple myeloma, Lancet, vol.374, pp.324-363, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00130206

A. Teitelbaum, A. Ba-mancini, H. Huang, and H. J. Henk, Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data, The Oncologist, vol.18, pp.37-45, 2013.

F. Donato, F. Gay, S. Bringhen, R. Troia, A. Palumbo et al., Monoclonal antibodybased therapy as a new treatment strategy in multiple myeloma, Expert Opin Biol Ther, vol.26, pp.199-213, 2012.

A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans et al.,

K. Dalva, G. Fuhler, J. Gratama, D. Hose, L. Kovarova et al., Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders, Haematologica, vol.93, pp.431-439, 2008.

R. Gupta, A. Bhaskar, L. Kumar, A. Sharma, and P. Jain, Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma, Am J Clin Pathol, vol.132, pp.728-760, 2009.

K. Raja, L. Kovarova, and R. Hajek, Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders, Br J Haematol, vol.149, pp.334-51, 2010.

A. C. Seegmiller, Y. Xu, R. W. Mckenna, and N. J. Karandikar, Immunophenotypic Differentiation Between Neoplastic Plasma Cells in Mature B-Cell Lymphoma vs Plasma Cell Myeloma, Am J Clin Pathol, vol.127, pp.176-81, 2007.

P. R. Tembhare, C. M. Yuan, D. Venzon, R. Braylan, N. Korde et al.,

D. Zuchlinsky, K. Calvo, R. Kurlander, M. Bhutani, N. Tageja et al.,

, Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases, Leuk Res, vol.38, pp.371-377, 2014.

J. Moreaux, D. Hose, T. Reme, J. E. Hundemer, M. Legouffe et al.,

P. Bourin, M. Moos, J. Corre, T. Möhler, D. Vos et al., CD200 is a new prognostic factor in multiple myeloma, Blood, vol.108, pp.4194-4201, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00130595

J. Moreaux, J. L. Veyrune, T. Reme, D. Vos, J. Klein et al., CD200: a putative therapeutic target in cancer, Biochem Biophys Res Commun, vol.366, pp.117-139, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00195258

H. Olteanu, A. M. Harrington, and S. H. Kroft, CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma, Am J Clin Pathol, vol.138, pp.867-76, 2012.

E. Spanoudakis, M. Hu, K. Naresh, E. Terpos, V. Melo et al.,

S. Abdalla, A. Rahemtulla, and A. Karadimitris, Regulation of multiple myeloma survival and progression by CD1d, Blood, vol.113, pp.2498-507, 2009.

D. Kim, J. Wang, S. B. Willingham, R. Martin, G. Wernig et al.,

, antibodies promote phagocytosis and inhibit the growth of human myeloma cells

, Leukemia, vol.26, pp.2538-2583, 2012.

J. M. Rendtlew-danielsen, L. M. Knudsen, I. M. Dahl, M. Lodahl, and T. Rasmussen,

, Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma

, Br J Haematol, vol.138, pp.756-60, 2007.

T. Alcindor, T. Kimlinger, and T. E. Witzig, High expression of CD59 and CD55 on benign and malignant plasma cells, Leuk Lymphoma, vol.47, pp.919-940, 2006.

A. Caraux, B. Klein, B. Paiva, C. Bret, A. Schmitz et al., Age-associated changes in counts and detailed characterization of 5 circulating normal CD138-and CD138+ plasma cells, Haematologica, vol.95, pp.1016-1020, 2010.

A. Caraux, L. Vincent, S. Bouhya, P. Quittet, J. Moreaux et al.,

J. Veyrune, G. Olivier, G. Cartron, and J. Rossi, Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?, 10 Oncotarget, vol.3, pp.1335-1347, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00802665

J. Martinez-lopez, J. J. Lahuerta, F. Pepin, M. González, S. Barrio et al., Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma, Blood, vol.123, pp.3073-3079, 2014.

G. Mateo, M. A. Montalbán, M. Vidriales, J. J. Lahuerta, M. V. Mateos et al., , 2008.

, Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy, J. Clin. Oncol, vol.26, pp.2737-2744

B. Paiva, M. Vidriales, J. Cerveró, G. Mateo, J. J. Pérez et al., , 2008.

, Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation, Blood, vol.112, pp.4017-4023

B. Paiva, M. Vídriales, M. Montalbán, J. J. Pérez, N. C. Gutiérrez et al., , 2012.

, Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials, Am. J. Pathol, vol.181, pp.1870-1878

B. Paiva, M. Chandia, N. Puig, M. Vidriales, J. J. Perez et al., The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapse multiple myeloma, Haematologica, 2014.

N. Aghaeepour, R. Nikolic, H. H. Hoos, and R. R. Brinkman, Rapid cell population identification in flow cytometry data, Cytom. Part J. Int. Soc. Anal. Cytol, vol.79, pp.6-13, 2011.

N. Aghaeepour, G. Finak, T. F. Consortium, T. D. Consortium, H. Hoos et al., Critical assessment of automated flow cytometry data analysis techniques, Nat. Methods, vol.10, pp.228-238, 2013.

I. Ahmad, R. Leblanc, S. Cohen, S. Lachance, T. Kiss et al., Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation, Bone Marrow Transplant, vol.51, pp.529-535, 2016.

D. Alapat, J. Coviello-malle, R. Owens, P. Qu, B. Barlogie et al., Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma, Am. J. Clin. Pathol, vol.137, pp.93-100, 2012.

T. Alcindor, T. Kimlinger, and T. E. Witzig, High expression of CD59 and CD55 on benign and malignant plasma cells, Leuk. Lymphoma, vol.47, pp.919-921, 2006.

R. Alexanian, J. Bonnet, E. Gehan, A. Haut, J. Hewlett et al., , 1972.

, Combination chemotherapy for multiple myeloma, Cancer, vol.30, pp.382-389

J. S. Allhusen and J. C. Conboy, The Ins and Outs of Lipid Flip-Flop, Acc. Chem. Res, 2016.

J. Almeida, A. Orfao, M. Ocqueteau, G. Mateo, M. Corral et al., High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma, Br. J. Haematol, vol.107, pp.121-131, 1999.

Y. Alsayed, J. Haessler, B. Barlogie, J. Crowley, and J. Shaughnessy, Gene expression profiling (GEP) of cd 138-purified plasma cells (pc) in previously treated multiple myeloma (PTMM): Validating prognostic models developed in newly diagnosed MM (NDMM), J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, p.8598, 2009.

Z. Amidzadeh, A. B. Behbahani, N. Erfani, S. Sharifzadeh, R. Ranjbaran et al., Assessment of different permeabilization methods of minimizing damage to the adherent cells for detection of intracellular RNA by flow cytometry, 2014.

, Avicenna J. Med. Biotechnol, vol.6, pp.38-46

M. N. Andersen, N. Abildgaard, M. B. Maniecki, H. J. Møller, and N. F. Andersen, , 2014.

, Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma, Eur. J. Haematol, vol.93, pp.41-47

M. Arroz, N. Came, P. Lin, W. Chen, C. Yuan et al., Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting, Cytometry B Clin. Cytom, vol.90, pp.31-39, 2016.

H. Avet-loiseau, J. Corre, V. Lauwers-cances, M. Chretien, N. Robillard et al.,

C. Gentil, B. Arnulf, and K. Belhadj, Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01300806

, Trial. Blood, vol.126, pp.191-191

D. C. Ayre and S. L. Christian, CD24: A Rheostat That Modulates Cell Surface Receptor Signaling of Diverse Receptors, Front. Cell Dev. Biol, vol.4, 2016.

L. Barbe, Mécanisme d'adhérence des leucocytes aux fibres synthétiques. Application à la filtration sanguine. phdthesis, 2001.

A. Bashashati and R. R. Brinkman, A Survey of Flow Cytometry Data Analysis Methods, Adv. Bioinforma, 2009.

R. Bataille, G. Jego, N. Robillard, S. Barille-nion, J. L. Harousseau et al., The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy, Haematologica, vol.91, pp.1234-1240, 2006.

I. Bates, Chapter 6 -Bone marrow biopsy, pp.115-130, 2006.

L. Benboubker, M. A. Dimopoulos, A. Dispenzieri, J. Catalano, A. R. Belch et al., Lenalidomide and dexamethasone in transplantineligible patients with myeloma, N. Engl. J. Med, vol.371, pp.906-917, 2014.

A. Ben-dor, R. Shamir, Y. , and Z. , Clustering gene expression patterns, J. Comput. Biol. J. Comput. Mol. Cell Biol, vol.6, pp.281-297, 1999.

Y. Benjamini and Y. Hochberg, Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing, J. R. Stat. Soc. Ser. B Methodol, vol.57, pp.289-300, 1995.

D. Billadeau, M. Blackstadt, P. Greipp, R. A. Kyle, M. M. Oken et al., , 1991.

, Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease, Blood, vol.78, pp.3021-3029

I. Binsky-ehrenreich, A. Marom, M. C. Sobotta, L. Shvidel, A. Berrebi et al., CD84 is a survival receptor for CLL cells, Oncogene, vol.33, pp.1006-1016, 2014.

J. Bladé, L. Rosiñol, M. T. Cibeira, M. Rovira, and E. Carreras, Hematopoietic stem cell transplantation for multiple myeloma beyond, Blood, vol.115, pp.3655-3663, 2010.

J. M. Bland and D. G. Altman, Statistical methods for assessing agreement between two methods of clinical measurement, Lancet Lond. Engl, vol.1, pp.307-310, 1986.

L. Boddy and C. W. Morris, Artificial neural networks for pattern recognition, Machine Learning Methods for Ecological Applications, pp.37-87, 1999.

G. R. Boersma-vreugdenhil, J. Kuipers, E. Van-stralen, T. Peeters, L. Michaux et al.,

P. L. Pearson, H. C. Clevers, and B. J. Bast, The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint, Br. J. Haematol, vol.126, pp.355-363, 2004.

N. Bolli, H. Avet-loiseau, D. C. Wedge, P. V. Loo, L. B. Alexandrov et al., Heterogeneity of genomic evolution and mutational profiles in multiple myeloma, Nat. Commun, vol.5, p.2997, 2014.

C. Botta, M. T. Di-martino, D. Ciliberto, M. Cucè, P. Correale et al., A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival, Blood Cancer J, vol.6, p.511, 2016.

L. Breiman, J. Friedman, C. J. Stone, and R. A. Olshen, Classification and Regression Trees, 1984.

A. M. Bruin, . De, C. Voermans, and M. A. Nolte, Impact of interferon-? on hematopoiesis, Blood, vol.124, pp.2479-2486, 2014.

C. Bueno, L. F. Lopes, and P. Menendez, , 2007.

B. V. Camp, B. G. Durie, C. Spier, M. D. Waele, I. V. Riet et al., Plasma cells in multiple myeloma express a natural killer cell-associated antigen, pp.56-57, 1990.

, Leu-19), Blood, vol.76, pp.377-382

M. A. Capelle, R. Gurny, A. , and T. , High throughput methods to characterize protein permeation and release, Int. J. Pharm, vol.350, pp.272-278, 2008.

A. Caraux, B. Klein, B. Paiva, C. Bret, A. Schmitz et al., Age-associated changes in counts and detailed characterization of circulating normal CD138-and CD138+ plasma cells, Haematologica, vol.95, pp.1016-1020, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00456476

A. Caraux, L. Vincent, S. Bouhya, P. Quittet, J. Moreaux et al., Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma, Oncotarget, vol.3, pp.1335-1347, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00802665

H. Chang, S. Sloan, D. Li, L. Zhuang, Q. Yi et al., , 2004.

T. Chen, T. Berno, and M. Zangari, Low-risk identification in multiple myeloma using a new 14-gene model, Eur. J. Haematol, vol.89, pp.28-36, 2012.

A. V. Chernyshev, P. A. Tarasov, K. A. Semianov, V. M. Nekrasov, A. G. Hoekstra et al.,

, Erythrocyte lysis in isotonic solution of ammonium chloride: theoretical modeling and experimental verification, J. Theor. Biol, vol.251, pp.93-107

M. Chesi and P. L. Bergsagel, Molecular pathogenesis of multiple myeloma: basic and clinical updates, Int. J. Hematol, vol.97, p.313, 2013.

M. Chesi, E. Nardini, R. S. Lim, K. D. Smith, W. M. Kuehl et al., The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts, Blood, vol.92, pp.3025-3034, 1998.

S. Chien, E. A. Schmalzer, M. M. Lee, T. Impelluso, and R. Skalak, Role of white blood cells in filtration of blood cell suspensions, Biorheology, vol.20, pp.11-27, 1983.

J. H. Christensen, P. V. Jensen, I. B. Kristensen, N. Abildgaard, M. Lodahl et al., , 2012.

, Characterization of potential CD138 negative myeloma "stem cells, Haematologica, vol.97, pp.18-20

G. J. Clark, M. Rao, X. Ju, and D. N. Hart, Novel human CD4+ T lymphocyte subpopulations defined by CD300a/c molecule expression, J. Leukoc. Biol, vol.82, pp.1126-1135, 2007.

C. M. Cohen and S. F. Foley, Biochemical characterization of complex formation by human erythrocyte spectrin, Biochemistry (Mosc.), vol.23, pp.6091-6098, 1984.

W. H. Coulter, F. L. Heuschkel, and R. H. Berg, , 1964.

F. A. Coumans, G. Van-dalum, M. Beck, and L. W. Terstappen, Filter Characteristics Influencing Circulating Tumor Cell Enrichment from Whole Blood, PLoS ONE, vol.8, 2013.

F. A. Coumans, G. Van-dalum, M. Beck, and L. W. Terstappen, Filtration parameters influencing circulating tumor cell enrichment from whole blood, PloS One, vol.8, 2013.

M. S. Czuczman, J. P. Leonard, S. Jung, J. L. Johnson, E. D. Hsi et al., , 2012.

, Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness, Ann. Oncol, vol.23, pp.2356-2362

T. R. Daniels, E. Ortiz-sánchez, R. Luria-pérez, R. Quintero, G. Helguera et al., An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies, J. Immunother. Hagerstown Md, vol.34, pp.500-508, 1997.

T. R. Daniels, E. Bernabeu, J. A. Rodríguez, S. Patel, M. Kozman et al., Transferrin receptors and the targeted delivery of therapeutic agents against cancer, Biochim. Biophys. Acta, vol.1820, pp.291-317, 2012.

O. Decaux, C. Hulin, and B. Grosbois, Traitement du myélome multiple, Médecine Thérapeutique, vol.13, pp.437-449, 2007.

O. Decaux, L. Lodé, F. Magrangeas, C. Charbonnel, W. Gouraud et al.,

J. Harousseau, P. Moreau, and R. Bataille, Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome, J. Clin. Oncol, vol.26, pp.4798-4805, 2008.

S. Demers, J. Kim, P. Legendre, and L. Legendre, Analyzing multivariate flow cytometric data in aquatic sciences, Cytometry, vol.13, pp.291-298, 1992.

J. L. Derisi, V. R. Iyer, and P. O. Brown, Exploring the metabolic and genetic control of gene expression on a genomic scale, Science, vol.278, pp.680-686, 1997.

M. A. Dimopoulos, T. Facon, P. G. Richardson, R. Z. Orlowski, J. F. San-miguel et al., ELOQUENT-1: A phase III, randomized, openlabel trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006), J. Clin. Oncol, vol.30, 2012.

M. A. Dimopoulos, A. Oriol, H. Nahi, J. San-miguel, N. J. Bahlis et al., Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma, N. Engl. J. Med, vol.375, pp.1319-1331, 2016.

F. Donato, F. Gay, S. Bringhen, R. Troia, and A. Palumbo, Monoclonal antibodies currently in Phase II and III trials for multiple myeloma, Expert Opin. Biol. Ther, pp.1-18, 2014.

J. J. Van-dongen, L. Lhermitte, S. Böttcher, J. Almeida, V. H. Van-der-velden et al., EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes, Leukemia, vol.26, pp.1908-1975, 2012.

N. W. Van-de-donk, S. Kamps, T. Mutis, and H. M. Lokhorst, Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma, Leukemia, vol.26, pp.199-213, 2012.

P. Dorwal, R. Thakur, and S. Rawat, CD138 expression in plasma cells is volatile and time-lag dependent, Egypt. J. Haematol, vol.39, pp.258-259, 2014.

B. G. Durie and S. E. Salmon, A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, vol.36, pp.842-854, 1975.

B. G. Durie, J. Harousseau, J. S. Miguel, J. Bladé, B. Barlogie et al.,

M. Dimopoulos, J. Westin, and P. Sonneveld, International uniform response criteria for multiple myeloma, Leukemia, vol.20, pp.1467-1473, 2006.

M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein, Cluster analysis and display of genome-wide expression patterns, Proc. Natl. Acad. Sci. U. S. A, vol.95, pp.14863-14868, 1998.

M. Engelhardt, E. Terpos, M. Kleber, F. Gay, R. Wäsch et al., European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma, Haematologica, vol.99, pp.232-242, 2014.

M. Faham, J. Zheng, M. Moorhead, V. E. Carlton, P. Stow et al., Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia, Blood, vol.120, pp.5173-5180, 2012.

M. Favreau, K. Vanderkerken, D. Elewaut, K. Venken, E. Menu et al., Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma, Oncotarget, vol.7, pp.23128-23140, 2016.

G. Finak, A. Bashashati, R. Brinkman, and R. Gottardo, Merging mixture components for cell population identification in flow cytometry, Adv. Bioinforma, p.247646, 2009.

A. Fleming, A Simple Method of Removing Leucocytes from Blood, Br. J. Exp. Pathol, vol.7, pp.281-286, 1926.

J. Flores-montero, R. De-tute, B. Paiva, J. J. Perez, S. Böttcher et al.,

Q. Lecrevisse and M. B. Vidriales, Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma, Cytometry B Clin, 2016.

. Cytom, , vol.90, pp.61-72

J. Flores-montero, R. De-tute, B. Paiva, J. J. Perez, S. Böttcher et al.,

Q. Lecrevisse and M. B. Vidriales, Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma, Cytometry B Clin, 2016.

. Cytom, , vol.90, pp.61-72

R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel et al.,

P. R. Greipp and I. R. Kirsch, Genetics and Cytogenetics of Multiple Myeloma, Cancer Res, vol.64, pp.1546-1558, 2004.

I. Frigyesi, J. Adolfsson, M. Ali, M. K. Christophersen, E. Johnsson et al.,

M. Hansson and B. Nilsson, Robust isolation of malignant plasma cells in multiple myeloma, 2014.

R. García-sanz, M. I. González-fraile, G. Mateo, J. M. Hernández, M. C. López-berges et al., Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients, Int. J. Cancer, vol.112, pp.884-889, 2004.

Y. Ge and S. C. Sealfon, flowPeaks: a fast unsupervised clustering for flow cytometry data via K-means and density peak finding, Bioinforma. Oxf. Engl, vol.28, pp.2052-2058, 2012.

D. C. Giammartino and E. Apostolou, The Chromatin Signature of Pluripotency: Establishment and Maintenance, Curr. Stem Cell Rep, vol.2, pp.255-262, 2016.

I. C. Glitza, G. Lu, R. Shah, Q. Bashir, N. Shah et al., Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma, Leuk. Lymphoma, vol.56, pp.602-607, 2015.

W. I. Gonsalves, S. V. Rajkumar, V. Gupta, W. G. Morice, M. M. Timm et al.,

F. K. Buadi, M. Q. Lacy, and P. Kapoor, Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma, Leukemia, vol.28, pp.2060-2065, 2014.

E. L. Gottfried, Lipids of human leukocytes: relation to cell type, J. Lipid Res, vol.8, pp.321-327, 1967.

C. W. Grant and H. M. Mcconnell, Glycophorin in lipid bilayers, Proc. Natl. Acad. Sci. U. S. A, vol.71, pp.4653-4657, 1974.

P. R. Greipp and S. Kumar, Plasma cell labeling index, Methods Mol. Med, vol.113, pp.25-35, 2005.

P. R. Greipp, J. S. Miguel, B. G. Durie, J. J. Crowley, B. Barlogie et al., International Staging System for Multiple Myeloma, J. Clin. Oncol, vol.23, pp.3412-3420, 2005.

R. Gupta, A. Bhaskar, L. Kumar, A. Sharma, and P. Jain, , 2009.

F. Hahne, N. Lemeur, R. R. Brinkman, B. Ellis, P. Haaland et al., flowCore: a Bioconductor package for high throughput flow cytometry, BMC Bioinformatics, vol.10, p.106, 2009.
URL : https://hal.archives-ouvertes.fr/inria-00426746

G. Hale and H. Waldmann, From Laboratory to Clinic : The Story of CAM PA TH-1, Methods Mol. Med, vol.40, pp.243-266, 2000.

J. Harousseau, M. Dreyling, and E. Group, Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO, vol.21, issue.5, pp.155-157, 2010.

L. Hartmann, J. S. Biggerstaff, D. B. Chapman, J. M. Scott, K. R. Johnson et al., Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques, Am. J. Clin. Pathol, vol.136, pp.712-720, 2011.

M. Heinze, M. Kofler, and C. Freund, Investigating the functional role of CD2BP2 in T cells, Int. Immunol, vol.19, pp.1313-1318, 2007.

T. Hideshima, A. , and K. C. , Molecular mechanisms of novel therapeutic approaches for multiple myeloma, Nat. Rev. Cancer, vol.2, pp.927-937, 2002.

B. Hoffman and D. A. Liebermann, Apoptotic signaling by c-MYC, Oncogene, vol.27, pp.6462-6472, 2008.

S. Holm, A Simple Sequentially Rejective Multiple Test Procedure. Scand, J. Stat, vol.6, pp.65-70, 1979.

D. Hose, T. Rème, T. Hielscher, J. Moreaux, T. Messner et al., Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma, Haematologica, vol.96, pp.87-95, 2011.

D. Hose, T. Reme, T. Hielscher, J. Moreaux, T. Messner et al., Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma, Haematologica, vol.96, pp.87-95, 2011.

E. Hubbell, W. Liu, M. , and R. , Robust estimators for expression analysis, Bioinforma. Oxf. Engl, vol.18, pp.1585-1592, 2002.

Z. Husak and M. N. Dworzak, CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity, Cell Death Dis, vol.3, p.425, 2012.

M. Ise, K. Matsubayashi, H. Tsujimura, and K. Kumagai, Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma, Clin. Lymphoma Myeloma Leuk, vol.16, pp.59-64, 2016.

S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin et al., A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma, Br. J. Haematol, vol.127, pp.165-172, 2004.

G. Jego, N. Robillard, D. Puthier, M. Amiot, F. Accard et al., Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells, Blood, vol.94, pp.701-712, 1999.
URL : https://hal.archives-ouvertes.fr/hal-01595831

T. Jeong, C. Park, H. Shim, S. Jang, H. Chi et al., Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells, 2012.

, Korean J. Hematol, vol.47, pp.260-266

M. Jourdan, M. Ferlin, E. Legouffe, M. Horvathova, J. Liautard et al., The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells, Br. J. Haematol, vol.100, pp.637-646, 1998.

M. Jourdan, A. Caraux, J. De-vos, G. Fiol, M. Larroque et al., An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization, Blood, vol.114, pp.5173-5181, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00446133

A. Kalff and A. Spencer, The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies, Blood Cancer J, vol.2, p.89, 2012.

J. L. Karnell, N. Dimasi, F. G. Karnell, R. Fleming, E. Kuta et al., CD19 and CD32b Differentially Regulate Human B Cell Responsiveness, J. Immunol. Author Choice, vol.192, pp.1480-1490, 2014.

A. Kassambara, D. Hose, J. Moreaux, B. A. Walker, A. Protopopov et al., Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma, Haematologica, vol.97, pp.622-630, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00727008

A. Kassambara, C. Gourzones-dmitriev, S. Sahota, T. Rème, J. Moreaux et al., A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy, Oncotarget, vol.5, pp.2487-2498, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01006634

A. Kassambara, T. Rème, M. Jourdan, T. Fest, D. Hose et al., , 2015.

, GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells, PLoS Comput. Biol, vol.11, p.1004077

E. Kastritis, E. Terpos, M. Roussou, M. Gavriatopoulou, M. Migkou et al., Evaluation of the Revised International Staging System (R-ISS) in an independent cohort of unselected patients with multiple myeloma, Haematologica, 2016.

D. Kim, J. Wang, S. B. Willingham, R. Martin, G. Wernig et al., Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells, Leukemia, vol.26, pp.2538-2545, 2012.

J. Kim, H. Lee, and S. Shin, Advances in the measurement of red blood cell deformability: A brief review, J. Cell. Biotechnol, vol.1, pp.63-79, 2015.

S. Kobayashi, R. Hyo, Y. Amitani, M. Tanaka, C. Hashimoto et al., Four-color flow cytometric analysis of myeloma plasma cells, Am. J. Clin. Pathol, vol.126, pp.908-915, 2006.

R. Kuiper, A. Broyl, Y. De-knegt, M. H. Van-vliet, E. H. Van-beers et al.,

G. Mulligan, W. Gregory, and G. Morgan, A gene expression signature for high-risk multiple myeloma, Leukemia, vol.26, pp.2406-2413, 2012.

A. Kukreja, S. Radfar, B. Sun, K. Insogna, and M. V. Dhodapkar, Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease, Blood, vol.114, pp.3413-3421, 2009.

S. Kumar, T. Kimlinger, and W. Morice, Immunophenotyping in multiple myeloma and related plasma cell disorders, Best Pract. Res. Clin. Haematol, vol.23, pp.433-451, 2010.

S. Kumar, B. Paiva, K. C. Anderson, B. Durie, O. Landgren et al., International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, vol.17, pp.328-346, 2016.

S. K. Kumar, J. R. Mikhael, F. K. Buadi, D. Dingli, A. Dispenzieri et al.,

S. R. Hayman and R. A. Kyle, Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines, Mayo Clin. Proc, vol.84, pp.1095-1110, 2009.

S. K. Kumar, J. H. Lee, J. J. Lahuerta, G. Morgan, P. G. Richardson et al.,

A. Hoering and P. Moreau, Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study, Leukemia, vol.26, pp.149-157, 2012.

R. A. Kyle, M. A. Gertz, T. E. Witzig, J. A. Lust, M. Q. Lacy et al., Review of 1027 patients with newly diagnosed multiple myeloma, Mayo Clin. Proc, vol.78, pp.21-33, 2003.

R. Van-laar, R. Flinchum, N. Brown, J. Ramsey, S. Riccitelli et al.,

J. D. Shaughnessy, Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use, BMC Med. Genomics, vol.7, p.25, 2014.

C. Lacroux, D. Bougard, C. Litaise, H. Simmons, F. Corbiere et al.,

S. Simon and S. Lugan, Impact of leucocyte depletion and prion reduction filters on TSE blood borne transmission, PloS One, vol.7, p.42019, 2012.

M. Ladetto, M. Brüggemann, L. Monitillo, S. Ferrero, F. Pepin et al., Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders, Leukemia, vol.28, pp.1299-1307, 2014.

J. J. Lahuerta, J. Martinez-lopez, J. Serna, J. Bladé, C. Grande et al., , 2000.

S. Lai, Y. Nakayama, J. M. Sequeira, and E. V. Quadros, Down-regulation of Transcobalamin Receptor TCblR/CD320 by siRNA Inhibits Cobalamin uptake and Proliferation of Cells in, Culture. Exp. Cell Res, vol.317, pp.1603-1607, 2011.

O. Landgren and R. G. Owen, Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient, Cytometry B Clin. Cytom, vol.90, pp.14-20, 2016.

O. Landgren and S. V. Rajkumar, New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.22, pp.5428-5433, 2016.

O. Landgren, N. Gormley, D. Turley, R. G. Owen, A. Rawstron et al.,

P. Wallace and B. Durie, Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium, Am. J. Hematol, vol.89, pp.1159-1160, 2014.

D. Lankry, T. L. Rovis, S. Jonjic, and O. Mandelboim, The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells, Eur. J. Immunol, vol.43, pp.2151-2161, 2013.

G. Lee, F. A. Spring, S. F. Parsons, T. J. Mankelow, L. L. Peters et al., Novel secreted isoform of adhesion molecule ICAM-4: potential regulator of membrane-associated ICAM-4 interactions, Blood, vol.101, pp.1790-1797, 2003.

R. Leo, M. Boeker, D. Peest, R. Hein, R. Bartl et al.,

, Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells, Ann. Hematol, vol.64, pp.132-139

S. M. Lewis, Chapter 2 -Reference ranges and normal values, pp.11-24, 2006.

P. Lin, R. Owens, G. Tricot, and C. S. Wilson, Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma, Am. J. Clin. Pathol, vol.121, pp.482-488, 2004.

H. Liu, C. Yuan, J. Heinerich, R. Braylan, M. Chang et al., Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study, Leuk. Lymphoma, vol.49, pp.306-314, 2008.

K. Lo, R. R. Brinkman, and R. Gottardo, Automated gating of flow cytometry data via robust model-based clustering, Cytom. Part J. Int. Soc. Anal. Cytol, vol.73, pp.321-332, 2008.

J. G. Lohr, P. Stojanov, S. L. Carter, P. Cruz-gordillo, M. S. Lawrence et al., Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy, Cancer Cell, vol.25, p.91, 2014.

S. Loisel, P. André, J. Golay, F. Buchegger, J. Kadouche et al., Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia, Mol. Cancer, vol.10, p.42, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00596532

H. M. Lokhorst, T. Plesner, J. P. Laubach, H. Nahi, P. Gimsing et al., Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma, N. Engl. J. Med, vol.373, pp.1207-1219, 2015.

R. E. Longley and D. Stewart, Recovery of functional human lymphocytes from Leukotrap filters, J. Immunol. Methods, vol.121, pp.33-38, 1989.

S. Lonial and J. L. Kaufman, Non-secretory myeloma: a clinician's guide, Oncol. Williston Park N, vol.27, p.930, 2013.

S. Lonial, M. Dimopoulos, A. Palumbo, D. White, S. Grosicki et al.,

P. Moreau, M. Mateos, and H. Magen, Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma, N. Engl. J. Med, vol.373, pp.621-631, 2015.

J. H. Lorent, J. Quetin-leclercq, and M. Mingeot-leclercq, The amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells, Org. Biomol. Chem, vol.12, pp.8803-8822, 2014.

E. Lugli, M. Roederer, and A. Cossarizza, Data Analysis in Flow Cytometry: The Future Just Started, Cytom. Part J. Int. Soc. Anal. Cytol, vol.77, pp.705-713, 2010.

D. Mahadevah, C. Mark, M. Lanasa, . Whelden, J. Susan et al.,

L. Camille, L. T. Bedrosian, and . Heffner, First-In-Human Phase I Dose Escalation Study of a, 2010.

H. Anti and -. Antibody, Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)

S. Mailankody, N. Korde, A. M. Lesokhin, N. Lendvai, H. Hassoun et al., Minimal residual disease in multiple myeloma: bringing the bench to the bedside, Nat. Rev. Clin. Oncol, vol.12, pp.286-295, 2015.

M. Manaargadoo-catin, A. Ali-cherif, J. Pougnas, and C. Perrin, Hemolysis by surfactants -A review, Adv. Colloid Interface Sci, vol.228, pp.1-16, 2016.

D. K. Marsee, B. Li, and D. M. Dorfman, Single tube, six-color flow cytometric analysis is a sensitive and cost-effective technique for assaying clonal plasma cells, Am. J. Clin. Pathol, vol.133, pp.694-699, 2010.

J. Martinez-lopez, E. Fernández-redondo, R. García-sánz, M. A. Montalbán, and P. Martínez-sánchez,

B. Pavia, M. V. Mateos, L. Rosiñol, M. Martín, and R. Ayala, Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study, Br. J. Haematol, vol.163, pp.581-589, 2013.

J. Martinez-lopez, J. J. Lahuerta, F. Pepin, M. González, S. Barrio et al., Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma, Blood, vol.123, pp.3073-3079, 2014.

J. Martinez-lopez, J. J. Lahuerta, F. Pepin, M. González, S. Barrio et al., Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma, Blood, vol.123, pp.3073-3079, 2014.

J. Martínez-lópez, B. Paiva, L. López-anglada, M. Mateos, T. Cedena et al., Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality, Blood, vol.126, pp.858-862, 2015.

B. Mascher, P. Schlenke, and M. Seyfarth, Expression and kinetics of cytokines determined by intracellular staining using flow cytometry, J. Immunol. Methods, vol.223, pp.115-121, 1999.

G. Mateo, M. A. Montalbán, M. Vidriales, J. J. Lahuerta, M. V. Mateos et al., Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy, J. Clin. Oncol, vol.26, pp.2737-2744, 2008.

M. Mateos, M. Cavo, A. J. Jakubowiak, R. L. Carson, M. Qi et al., A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone), J. Clin, 2015.

, Oncol, vol.33

G. Matheis, M. Scholz, A. Simon, O. Dzemali, and A. Moritz, Leukocyte filtration in cardiac surgery: a review, Perfusion, vol.16, pp.361-370, 2001.

C. Mathiot, J. Teillaud, M. Elmalek, V. Mosseri, L. Euller-ziegler et al., Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma, J. Clin. Immunol, vol.13, pp.41-48, 1993.

C. Mathiot, J. Galon, E. Tartour, J. L. Teillaud, T. Facon et al.,

, Soluble CD16 in Plasma Cell Dyscrasias, Leuk. Lymphoma, vol.32, pp.467-474

S. Mathis, N. Chapuis, J. Borgeot, M. Maynadié, M. Fontenay et al.,

, antibody combination and analysis strategy, Cytometry B Clin. Cytom

T. P. Meyer, I. Zehnter, B. Hofmann, J. Zaisserer, J. Burkhart et al., Filter Buffy Coats (FBC): a source of peripheral blood leukocytes recovered from leukocyte depletion filters, J. Immunol. Methods, vol.307, pp.150-166, 2005.

J. Moreaux, D. Hose, T. Reme, E. Jourdan, M. Hundemer et al., CD200 is a new prognostic factor in multiple myeloma, Blood, vol.108, pp.4194-4197, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00130595

J. Moreaux, J. L. Veyrune, T. Reme, J. De-vos, and B. Klein, CD200: a putative therapeutic target in cancer, Biochem. Biophys. Res. Commun, vol.366, pp.117-122, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00195258

J. Moreaux, B. Klein, R. Bataille, G. Descamps, S. Maïga et al., A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, pp.574-582, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00550232

J. Moreaux, T. Rème, W. Leonard, J. Veyrune, G. Requirand et al.,

B. Klein, Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors, Mol. Cancer Ther, vol.11, pp.2685-2692, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00760269

G. J. Morgan, B. A. Walker, and F. E. Davies, The genetic architecture of multiple myeloma, 2012.

, Nat. Rev. Cancer, vol.12, pp.335-348

W. G. Morice, C. A. Hanson, S. Kumar, L. A. Frederick, C. E. Lesnick et al., Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders, Leukemia, vol.21, pp.2043-2046, 2007.

S. J. Morris, Leukocyte reduction in cardiovascular surgery, Perfusion, vol.16, pp.371-380, 2001.

V. E. Muccio, E. Saraci, M. Gilestro, V. Gattei, A. Zucchetto et al., Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents, Cytometry B Clin. Cytom, vol.90, pp.81-90, 2016.

G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. J. Chng et al.,

P. Richardson, Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib, Blood, vol.109, pp.3177-3188, 2007.

R. F. Murphy, , 1985.

K. Nagata, T. Nakamura, F. Kitamura, S. Kuramochi, S. Taki et al.,

, The Ig alpha/Igbeta heterodimer on mu-negative proB cells is competent for transducing signals to induce early B cell differentiation, Immunity, vol.7, pp.559-570

S. Nakayama, T. Yokote, Y. Hirata, K. Iwaki, T. Akioka et al., An approach for diagnosing plasma cell myeloma by threecolor flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells, Diagn. Pathol, vol.7, p.131, 2012.

U. Naumann, G. Luta, and M. P. Wand, The curvHDR method for gating flow cytometry samples, BMC Bioinformatics, vol.11, p.44, 2010.

F. P. O&apos;connell, J. L. Pinkus, and G. S. Pinkus, CD138 (Syndecan-1), a Plasma Cell Marker, Am. J. Clin. Pathol, vol.121, pp.254-263, 2004.

M. Ocqueteau, A. Orfao, J. Almeida, J. Blade, M. Gonzalez et al., Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma, Am. J. Pathol, vol.152, pp.1655-1665, 1998.

T. A. Oldaker, P. K. Wallace, and D. Barnett, Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma, Cytometry B Clin. Cytom, vol.90, pp.40-46, 2016.

H. Olteanu, A. M. Harrington, and S. H. Kroft, CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma, Am. J. Clin. Pathol, vol.138, pp.867-876, 2012.

T. Paíno, B. Paiva, J. M. Sayagués, I. Mota, T. Carvalheiro et al.,

M. L. Sanchez and P. Barcena, Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential, Leukemia, vol.29, pp.1186-1194, 2015.

B. Paiva, M. Vidriales, J. Cerveró, G. Mateo, J. J. Pérez et al., Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation, Blood, vol.112, pp.4017-4023, 2008.

B. Paiva, J. Almeida, M. Pérez-andrés, G. Mateo, A. López et al., Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders, Cytometry B Clin. Cytom, vol.78, pp.239-252, 2010.

B. Paiva, J. Martinez-lopez, M. Vidriales, M. Mateos, M. Montalban et al., Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma, J. Clin. Oncol, vol.29, pp.1627-1633, 2011.

B. Paiva, N. C. Gutiérrez, L. Rosiñol, M. Vídriales, M. Montalbán et al., High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma, Blood, vol.119, pp.687-691, 2012.

B. Paiva, M. Vídriales, M. Montalbán, J. J. Pérez, N. C. Gutiérrez et al., Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials, Am. J. Pathol, vol.181, pp.1870-1878, 2012.

B. Paiva, T. Paino, J. Sayagues, M. Garayoa, L. San-segundo et al., Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile, Blood, vol.122, pp.3591-3598, 2013.

B. Paiva, M. Chandia, N. Puig, M. Vidriales, J. J. Perez et al., , 2014.

B. Paiva, J. J. Van-dongen, and A. Orfao, New criteria for response assessment: role of minimal residual disease in multiple myeloma, Blood, vol.125, pp.3059-3068, 2015.

B. Paiva, M. Chandia, N. Puig, M. Vidriales, J. J. Perez et al., The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma, Haematologica, vol.100, pp.53-55, 2015.

B. Paiva, M. Cedena, N. Puig, P. Arana, M. Vidriales et al., Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients, Blood, vol.127, pp.3165-3174, 2016.

B. Paiva, N. Puig, M. T. Cedena, B. G. De-jong, Y. Ruiz et al.,

D. Alignani and J. A. Delgado, Differentiation stage of myeloma plasma cells: biological and clinical significance, Leukemia, vol.31, pp.382-392, 2017.

A. Palumbo, H. Avet-loiseau, S. Oliva, H. M. Lokhorst, H. Goldschmidt et al., Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, J. Clin. Oncol, vol.33, pp.2863-2869, 2015.

A. Palumbo, A. Chanan-khan, K. Weisel, A. K. Nooka, T. Masszi et al., Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma, N. Engl. J. Med, vol.375, pp.754-766, 2016.

D. R. Parks, M. Roederer, and W. A. Moore, A new "Logicle" display method avoids deceptive effects of logarithmic scaling for low signals and compensated data, Cytom. Part J. Int. Soc. Anal, 2006.

, Cytol, vol.69, pp.541-551

V. Peceliunas, A. Janiulioniene, R. Matuzeviciene, and L. Griskevicius, , 2011.

, Cytometry B Clin. Cytom, vol.80, pp.318-323

O. D. Perez, P. O. Krutzik, and G. P. Nolan, Flow cytometric analysis of kinase signaling cascades, Methods Mol. Biol. Clifton NJ, vol.263, pp.67-94, 2004.

R. N. Pietersz, P. F. Van-der-meer, and M. J. Seghatchian, Update on Leucocyte Depletion of Blood Components by Filtration, Transfus. Sci, vol.19, pp.321-328, 1998.

A. Plonquet, Différenciation lymphocytaire B normale, Rev. Francoph. Lab, pp.27-35, 2013.

F. Pojero, J. Flores-montero, L. Sanoja, J. J. Pérez, N. Puig et al., Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases, Cytometry B Clin. Cytom, vol.90, pp.91-100, 2016.

E. V. Prochownik, c-Myc: linking transformation and genomic instability, Curr. Mol. Med, vol.8, pp.446-458, 2008.

N. Puig, M. E. Sarasquete, A. Balanzategui, J. Martínez, B. Paiva et al., Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry, Leukemia, vol.28, pp.391-397, 2014.

M. Putkonen, V. Kairisto, V. Juvonen, T. Pelliniemi, A. Rauhala et al., Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma, Eur. J. Haematol, vol.85, pp.416-423, 2010.

S. Pyne, X. Hu, K. Wang, E. Rossin, T. Lin et al., , 2009.

, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.8519-8524

Y. Qian, C. Wei, . Eun-hyung, F. Lee, J. Campbell et al., Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data, Cytometry B Clin. Cytom, 2010.

E. V. Quadros and J. M. Sequeira, Cellular Uptake of Cobalamin: Transcobalamin and the, 2013.

/. Tcblr and . Receptor, Biochimie, vol.95, pp.1008-1018

E. V. Quadros, Y. Nakayama, and J. M. Sequeira, Saporin Conjugated Monoclonal Antibody to the Transcobalamin Receptor TCblR/CD320 Is Effective in Targeting and Destroying Cancer Cells, J. Cancer Ther, vol.4, pp.1074-1081, 2013.

M. S. Raab, K. Podar, I. Breitkreutz, P. G. Richardson, A. et al., Multiple myeloma, Lancet, vol.374, pp.324-339, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00130206

K. R. Raja, L. Kovarova, and R. Hajek, Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders, Br. J. Haematol, vol.149, pp.334-351, 2010.

S. V. Rajkumar, Evolving diagnostic criteria for multiple myeloma, Hematol. Am. Soc. Hematol. Educ. Program, pp.272-278, 2015.

S. V. Rajkumar, S. R. Hayman, M. Q. Lacy, A. Dispenzieri, S. M. Geyer et al.,

S. Kumar, P. R. Greipp, and R. Fonseca, Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma, Blood, vol.106, pp.4050-4053, 2005.

S. V. Rajkumar, R. A. Kyle, T. M. Therneau, L. J. Melton, A. R. Bradwell et al., Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance, Blood, vol.106, pp.812-817, 2005.

S. V. Rajkumar, J. Harousseau, B. Durie, K. C. Anderson, M. Dimopoulos et al., Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, vol.117, pp.4691-4695, 2011.

A. C. Rawstron, F. E. Davies, R. Dasgupta, A. J. Ashcroft, R. Patmore et al., Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation, Blood, vol.100, pp.3095-3100, 2002.

A. C. Rawstron, G. Laycock-brown, G. Hale, F. E. Davies, G. J. Morgan et al., CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy, Haematologica, vol.91, pp.1577-1578, 2006.

A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans et al., Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders, Haematologica, vol.93, pp.431-438, 2008.

A. C. Rawstron, J. A. Child, R. M. De-tute, F. E. Davies, W. M. Gregory et al., Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.31, pp.2540-2547, 2013.

A. C. Rawstron, W. M. Gregory, R. M. De-tute, F. E. Davies, S. E. Bell et al., Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction, Blood, vol.125, pp.1932-1935, 2015.

S. Reid, S. Yang, R. Brown, K. Kabani, E. Aklilu et al., , 2010.

, Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma, Int. J. Lab. Hematol, vol.32, pp.190-196

R. A. Reithmeier, J. R. Casey, A. C. Kalli, M. S. Sansom, Y. Alguel et al., Band 3, the human red cell chloride/bicarbonate anion exchanger (AE1, SLC4A1), in a structural context, Biochim. Biophys. Acta, vol.1858, pp.1507-1532, 2016.

T. Rème, D. Hose, C. Theillet, and B. Klein, Modeling risk stratification in human cancer, Bioinforma. Oxf. Engl, vol.29, pp.1149-1157, 2013.

T. Rème, D. Hose, C. Theillet, and B. Klein, Modeling risk stratification in human cancer, Bioinformatics, vol.29, pp.1149-1157, 2013.

J. M. Rendtlew-danielsen, L. M. Knudsen, I. M. Dahl, M. Lodahl, and T. Rasmussen, , 2007.

, Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma, Br. J. Haematol, vol.138, pp.756-760

M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law et al., limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res, vol.43, p.47, 2015.

N. Robillard, C. Pellat-deceunynck, and R. Bataille, Phenotypic characterization of the human myeloma cell growth fraction, Blood, vol.105, pp.4845-4848, 2005.

N. Robillard, M. C. Béné, P. Moreau, and S. Wuillème, A single-tube multiparameter seven, 2013.

N. Robillard, M. C. Béné, P. Moreau, and S. Wuillème, A single-tube multiparameter seven, 2013.

N. Robillard, S. Wuillème, P. Moreau, and M. C. Béné, Immunophenotype of Normal and Myelomatous Plasma, vol.5, 2014.

A. Rolink, U. Grawunder, T. H. Winkler, H. Karasuyama, and F. Melchers, IL-2 receptor alpha chain (CD25, TAC) expression defines a crucial stage in pre-B cell development, Int. Immunol, vol.6, pp.1257-1264, 1994.

H. Romero-ramírez, M. T. Morales-guadarrama, R. Pelayo, R. López-santiago, and S. ,

L. Argumedo, CD38 expression in early B-cell precursors contributes to extracellular signalregulated kinase-mediated apoptosis, Immunology, vol.144, pp.271-281, 2015.

N. Rongeat, Utilisation de sources polychromes pour le diagnostic cytologique : application à l'hématologie (Limoges), 2011.

P. J. Rousseeuw, E. Trauwaert, and L. Kaufman, Fuzzy clustering with high contrast, J. Comput. Appl. Math, vol.64, pp.81-90, 1995.

A. I. Saeed, N. K. Bhagabati, J. C. Braisted, W. Liang, V. Sharov et al., TM4 microarray software suite, Methods Enzymol, vol.411, pp.134-193, 2006.

M. E. Salama, S. Du, O. Efimova, N. M. Heikal, E. Wendlandt et al., Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities, Leuk. Lymphoma, vol.56, pp.426-433, 2015.

J. F. San-miguel, R. García-sanz, M. González, M. J. Moro, J. M. Hernández et al., A new staging system for multiple myeloma based on the number of S-phase plasma cells, Blood, vol.85, pp.448-455, 1995.

L. Sanjurjo, G. Aran, N. Roher, A. F. Valledor, and M. Sarrias, AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease, J. Leukoc. Biol, vol.98, pp.173-184, 2015.

M. E. Sarasquete, R. García-sanz, D. González, J. Martínez, G. Mateo et al., Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry, Haematologica, vol.90, pp.1365-1372, 2005.

D. Sarkar, N. Le-meur, and R. Gentleman, Using flowViz to visualize flow cytometry data, Bioinforma. Oxf. Engl, vol.24, pp.878-879, 2008.

M. Schena, D. Shalon, R. W. Davis, and P. O. Brown, Quantitative monitoring of gene expression patterns with a complementary DNA microarray, Science, vol.270, pp.467-470, 1995.

M. Schmidt-hieber, M. L. Gutiérrez, M. Pérez-andrés, B. Paiva, A. Rasillo et al.,

J. M. Sayagués, A. Lopez, P. Bárcena, and M. L. Sanchez, Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells, Haematologica, vol.98, pp.279-287, 2013.

M. Schmidt-hieber, M. L. Gutiérrez, M. Pérez-andrés, B. Paiva, A. Rasillo et al.,

J. M. Sayagués, A. Lopez, P. Bárcena, and M. L. Sanchez, Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells, Haematologica, vol.98, pp.279-287, 2013.

B. Scholkopf and A. J. Smola, Learning with Kernels: Support Vector Machines, Regularization, Optimization, and Beyond, 2001.

S. Schreier, S. V. Malheiros, and E. De-paula, Surface active drugs: self-association and interaction with membranes and surfactants. Physicochemical and biological aspects, Biochim. Biophys. Acta, vol.1508, pp.210-234, 2000.

A. C. Seegmiller, Y. Xu, R. W. Mckenna, and N. J. Karandikar, Immunophenotypic Differentiation Between Neoplastic Plasma Cells in Mature B-Cell Lymphoma vs Plasma Cell Myeloma, Am. J. Clin. Pathol, vol.127, pp.176-181, 2007.

A. Shah, New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab, Ther. Clin. Risk Manag, vol.11, pp.1113-1122, 2015.

J. D. Shaughnessy, F. Zhan, B. E. Burington, Y. Huang, S. Colla et al.,

B. Kordsmeier, C. Randolph, and D. R. Williams, A validated gene expression model of highrisk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, vol.109, pp.2276-2284, 2007.

R. Silvennoinen, T. Lundan, V. Kairisto, T. Pelliniemi, M. Putkonen et al.,

P. Mäntymaa, S. Siitonen, and L. Uotila, Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma, Blood Cancer J, vol.4, p.250, 2014.

S. Singh and A. Kumar, Leukocyte depletion for safe blood transfusion, Biotechnol. J, vol.4, pp.1140-1151, 2009.

B. L. Smith, G. M. Preston, F. A. Spring, D. J. Anstee, A. et al., Human red cell aquaporin CHIP. I. Molecular characterization of ABH and Colton blood group antigens, J. Clin. Invest, vol.94, pp.1043-1049, 1994.

P. Sondergeld, N. W. Van-de-donk, P. G. Richardson, and T. Plesner, Monoclonal antibodies in myeloma, Clin. Adv. Hematol. Oncol. HO, vol.13, pp.599-609, 2015.

T. Sonoki, L. Harder, D. E. Horsman, L. Karran, I. Taniguchi et al., Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies, Blood, vol.98, pp.2837-2844, 2001.

J. M. Sosa, N. D. Nielsen, S. M. Vignes, T. G. Chen, and S. S. Shevkoplyas, The relationship between red blood cell deformability metrics and perfusion of an artificial microvascular network, 2014.

, Clin. Hemorheol. Microcirc, vol.57, pp.291-305

S. Soverini, M. Cavo, C. Cellini, C. Terragna, E. Zamagni et al., Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation, Blood, vol.102, pp.1588-1594, 2003.

E. Spanoudakis, M. Hu, K. Naresh, E. Terpos, V. Melo et al.,

A. Rahemtulla and A. Karadimitris, Regulation of multiple myeloma survival and progression by CD1d, Blood, vol.113, pp.2498-2507, 2009.

P. T. Spellman, G. Sherlock, M. Q. Zhang, V. R. Iyer, K. Anders et al., Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization, Mol. Biol. Cell, vol.9, pp.3273-3297, 1998.

M. Stetler-stevenson, B. Paiva, L. Stoolman, P. Lin, J. L. Jorgensen et al., Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition, Cytometry B Clin. Cytom, vol.90, pp.26-30, 2016.

A. Sturn, J. Quackenbush, and Z. Trajanoski, Genesis: cluster analysis of microarray data, Bioinforma. Oxf. Engl, vol.18, pp.207-208, 2002.

I. P. Sugár and S. C. Sealfon, Misty Mountain clustering: application to fast unsupervised flow cytometry gating, BMC Bioinformatics, vol.11, p.502, 2010.

E. Suyan?, G. T. Sucak, N. Akyürek, S. ?ahin, N. A. Baysal et al., Tumorassociated macrophages as a prognostic parameter in multiple myeloma, Ann. Hematol, vol.92, p.669, 2013.

T. Tanaka, K. Ichimura, Y. Sato, K. Takata, T. Morito et al., Frequent downregulation or loss of CD79a expression in plasma cell myelomas: potential clue for diagnosis, Pathol. Int, vol.59, pp.804-808, 2009.

A. Teitelbaum, A. Ba-mancini, H. Huang, and H. J. Henk, Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data, The Oncologist, vol.18, pp.37-45, 2013.

P. R. Tembhare, C. M. Yuan, D. Venzon, R. Braylan, N. Korde et al., Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases, Leuk. Res, vol.38, pp.371-376, 2014.

L. W. Terstappen, S. Johnsen, I. M. Segers-nolten, and M. R. Loken, Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry, Blood, vol.76, pp.1739-1747, 1990.

A. Tessier-marteau, F. Geneviève, A. Godon, L. Macchi, and M. Zandecki, Automated hematology analysers and spurious counts, Ann. Biol. Clin, vol.68, pp.393-407, 2010.

E. Tian, J. Sawyer, O. W. Stephens, R. Tytarenko, S. Thanendrarajan et al., Translocations and Jumping Rearrangements at 8q24, 2016.

, Result in over-Expression of MYC and are Key Drivers of Disease Progression, Blood, vol.128, pp.115-115

T. Tohami, L. Drucker, H. Shapiro, J. Radnay, and M. Lishner, Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential, FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol, vol.21, pp.691-699, 2007.

V. G. Tusher, R. Tibshirani, C. , and G. , Significance analysis of microarrays applied to the ionizing radiation response, Proc. Natl. Acad. Sci. U. S. A, vol.98, pp.5116-5121, 2001.

R. M. De-tute, A. S. Jack, J. A. Child, G. J. Morgan, R. G. Owen et al., A singletube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma, Leukemia, vol.21, pp.2046-2049, 2007.

R. M. De-tute, A. C. Rawstron, W. M. Gregory, J. A. Child, F. E. Davies et al., Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen, Haematologica, vol.101, pp.69-71, 2016.

V. H. V-van-der-velden, A. Hochhaus, G. Cazzaniga, T. Szczepanski, J. Gabert et al., Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects, Leukemia, vol.17, pp.1013-1034, 2003.

C. P. Verschoor, A. Lelic, J. L. Bramson, and D. M. Bowdish, An Introduction to Automated Flow Cytometry Gating Tools and Their Implementation, vol.6, 2015.

R. Vij, A. Mazumder, M. Klinger, D. O&apos;dea, J. Paasch et al., Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients, Clin. Lymphoma Myeloma Leuk, vol.14, pp.131-139, 2014.

J. Vives-rego, P. Lebaron, C. , and G. N. , Current and future applications of flow cytometry in aquatic microbiology, FEMS Microbiol. Rev, vol.24, pp.429-448, 2000.

A. J. De-vries, Y. J. Gu, W. J. Post, P. Vos, I. Stokroos et al., Leucocyte depletion during cardiac surgery: a comparison of different filtration strategies, Perfusion, vol.18, pp.31-38, 2003.

S. Wagner, A. Myrup, and C. Celluzzi, Method for enriching adherent monocyte populations, 2006.

B. A. Walker, E. M. Boyle, C. P. Wardell, A. Murison, D. B. Begum et al., Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.33, pp.3911-3920, 2015.

J. Wang, V. Nygaard, B. Smith-sørensen, E. Hovig, and O. Myklebost, MArray: analysing single, replicated or reversed microarray experiments, Bioinforma. Oxf. Engl, vol.18, pp.1139-1140, 2002.

Y. Wang, M. Inger, H. Jiang, H. Tenenbaum, and M. Glogauer, CD109 plays a role in osteoclastogenesis, PloS One, vol.8, 2013.

M. F. Wilkins, S. A. Hardy, L. Boddy, and C. W. Morris, Comparison of five clustering algorithms to classify phytoplankton from flow cytometry data, Cytometry, vol.44, pp.210-217, 2001.
URL : https://hal.archives-ouvertes.fr/hal-01651729

E. L. Williams, A. L. Tutt, S. A. Beers, R. R. French, C. H. Chan et al., Immunotherapy targeting inhibitory Fc? receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization, J. Immunol. Baltim. Md, pp.4130-4140, 2013.

L. M. Williamson, Leucocyte Depletion Of The Blood Supply -How Will Patients Benefit?, Br. J. Haematol, vol.110, pp.256-272, 2000.

Z. Xiang, A. J. Cutler, R. J. Brownlie, K. Fairfax, K. E. Lawlor et al., FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis, Nat. Immunol, vol.8, pp.419-429, 2007.

I. Yakoub-agha, M. Attal, C. Dumontet, V. Delannoy, P. Moreau et al., Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM), Hematol. J. Off. J. Eur. Haematol. Assoc. EHA, vol.3, pp.185-192, 2002.

Y. Yawata, Composition of Normal Red Cell Membranes, In Cell Membrane, pp.27-46, 2003.

T. You, W. Hu, X. Ge, J. Shen, and X. Qin, Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells, Cell. Mol. Immunol, vol.8, pp.157-163, 2011.

L. Yu, P. Warner, B. Warner, D. Recktenwald, D. Yamanishi et al., Whole blood leukocytes isolation with microfabricated filter for cell analysis, Cytom. Part J. Int. Soc. Anal. Cytol, vol.79, pp.1009-1015, 2011.

S. Yusa, S. Ohnishi, T. Onodera, and T. Miyazaki, AIM, a murine apoptosis inhibitory factor, induces strong and sustained growth inhibition of B lymphocytes in combination with TGF-?1, Eur. J. Immunol, vol.29, pp.1086-1093, 1999.

F. Zagouri, E. Terpos, E. Kastritis, and M. A. Dimopoulos, Emerging antibodies for the treatment of multiple myeloma, Expert Opin. Emerg. Drugs, vol.21, pp.225-237, 2016.

H. Zare, P. Shooshtari, A. Gupta, and R. R. Brinkman, Data reduction for spectral clustering to analyze high throughput flow cytometry data, BMC Bioinformatics, vol.11, p.403, 2010.

P. Zelnickova, M. Faldyna, H. Stepanova, J. Ondracek, and F. Kovaru, Intracellular cytokine detection by flow cytometry in pigs: Fixation, permeabilization and cell surface staining, J. Immunol. Methods, vol.327, pp.18-29, 2007.

F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura et al., The molecular classification of multiple myeloma, Blood, vol.108, pp.2020-2028, 2006.

X. Zheng, S. Abroun, K. Otsuyama, H. Asaoku, and M. M. Kawano, Heterogeneous expression of CD32 and CD32-mediated growth suppression in human myeloma cells, Haematologica, vol.91, pp.920-928, 2006.

P. Zhou, R. L. Comenzo, A. B. Olshen, E. Bonvini, S. Koenig et al.,

S. Jhanwar and J. W. Young, CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy, Blood, vol.111, pp.3403-3406, 2008.

Y. Zhou, B. Barlogie, J. D. Shaughnessy, and J. , The molecular characterization and clinical management of multiple myeloma in the post-genome era, Leukemia, vol.23, 1941.